DOI QR코드

DOI QR Code

Radiofrequency Ablation of Papillary Thyroid Microcarcinoma: A 10-Year Follow-Up Study

갑상선 미세유두암의 고주파 절제술 후 10년 경과 관찰

  • Yoo Kyeong Seo (Department of Radiology, Kangwon National University Hospital) ;
  • Seong Whi Cho (Department of Radiology, Kangwon National University Hospital) ;
  • Jung Suk Sim (Department of Radiology, Withsim Clinic) ;
  • Go Eun Yang (Department of Radiology, Kangwon National University Hospital) ;
  • Woojin Cho (Department of Otolaryngology and Head and Neck Surgery, Withsim Clinic)
  • Received : 2020.06.25
  • Accepted : 2020.10.15
  • Published : 2021.07.01

Abstract

Purpose To investigate the efficacy and safety of radiofrequency ablation (RFA) for papillary thyroid microcarcinoma (PTMC) after > 10 years of follow-up. Materials and Methods This study included five patients who underwent RFA to treat PTMCs (five lesions, mean diameter 0.5 cm, range 0.4-0.7 cm) between November 2006 and December 2009. The inclusion criteria were histopathologically confirmed PTMCs, a single PTMC lesion without extrathyroidal extension, no metastasis, and ineligibility or refusal to undergo surgery. RFA was performed by a single radiologist using a radiofrequency generator and an internally cooled electrode. We retrospectively analyzed the procedure-induced complications, serial changes in ablated tumors, recurrence, and local as well as lymph node metastasis based on data obtained from medical records and radiological images. Results The mean follow-up period was 130.6 months (range 121-159 months). Three patients underwent a single RFA session, and two patients underwent two RFA sessions. We observed no procedure-induced complications. Three tumors completely disappeared after ablation, and ablation of the other two tumors resulted in the formation of a small scar that showed long-term stability (mean duration 16.8 months, range 12-27 months). At the last follow-up, no patient showed recurrence or lymph node metastasis, and serum thyroglobulin levels were within normal limits in all patients. Conclusion RFA may be effective and safe to treat low-risk PTMC in patients who refuse or are ineligible for surgery.

목적 이 연구는 갑상선 미세유두암을 고주파 절제술로 치료한 후 10년 이상 경과 관찰한 환자들의 결과를 통해 효과와 안전성을 평가하고자 했다. 대상과 방법 2006년 11월부터 2009년 12월까지 갑상선 미세유두암을 고주파 절제술로 치료받은 환자 5명을 대상으로 하였다. 이 환자들은 모두 조직검사를 통해 갑상선 미세유두암으로 진단을 받았고, 병변은 갑상선 내에 국한되어 있었으며, 전이의 증거가 없었고, 수술이나 전신마취가 의학적으로 부적합하거나 수술을 거부한 환자들이었다. 고주파 절제술은 고주파 발생기와 냉각기를 사용하여 한 명의 영상의학과 의사가 시행하였다. 우리는 시술과 연관된 부작용, 소작된 종양의 변화, 재발 여부, 국소 또는 림프절 전이 등에 대해 초음파 영상 소견과 의무 기록을 토대로 분석하였다. 결과 평균 경과 관찰기간은 130.6개월(범위, 121~159개월) 이었다. 세 명의 환자는 한 번의 고주파 절제술을, 두 명의 환자는 두 번의 시술을 받았다. 다섯 명의 환자 모두 시술과 연관된 부작용은 보이지 않았다. 다섯 개 중 세 개의 종양은 시술 후 완전히 사라졌으며 두 개의 종양은 최소한의 흔적으로 남아 평균 16.8개월의 경과 관찰기간 동안 큰 변화가 없었다. 가장 최근의 경과관찰에서 다섯 명의 환자 모두 국소 전이나 림프절 전이는 보이지 않았고 갑상선 글로불린(thyroglobulin)의 수치도 정상 범위였다. 결론 고주파 절제술은 수술에 부적합하거나 수술을 거부하는 저위험 갑상선 미세유두암 환자들에 대해서 효과적이고 안전한 치료법이 될 수 있다.

Keywords

References

  1. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016;26:1-133  https://doi.org/10.1089/thy.2015.0020
  2. Liu Y, Su L, Xiao H. Review of factors related to the thyroid cancer epidemic. Int J Endocrinol 2017;2017:5308635 
  3. Sakai T, Sugitani I, Ebina A, Fukuoka O, Toda K, Mitani H, et al. Active surveillance for T1bN0M0 papillary thyroid carcinoma. Thyroid 2019;29:59-63  https://doi.org/10.1089/thy.2018.0462
  4. Shin JH, Baek JH, Chung J, Ha EJ, Kim JH, Lee YH, et al. Ultrasonography diagnosis and imaging-based management of thyroid nodules: revised Korean Society of Thyroid Radiology Consensus Statement and Recommendations. Korean J Radiol 2016;17:370-395  https://doi.org/10.3348/kjr.2016.17.3.370
  5. Sanabria A, Kowalski LP, Shah JP, Nixon IJ, Angelos P, Williams MD, et al. Growing incidence of thyroid carcinoma in recent years: factors underlying overdiagnosis. Head Neck 2018;40:855-866  https://doi.org/10.1002/hed.25029
  6. Russ G. Risk stratification of thyroid nodules on ultrasonography with the French TI-RADS: description and reflections. Ultrasonography 2016;35:25-38  https://doi.org/10.14366/usg.15027
  7. Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer 2009;115:3801-3807  https://doi.org/10.1002/cncr.24416
  8. Ito Y, Miyauchi A, Inoue H, Fukushima M, Kihara M, Higashiyama T, et al. An observational trial for papillary thyroid microcarcinoma in Japanese patients. World J Surg 2010;34:28-35  https://doi.org/10.1007/s00268-009-0303-0
  9. Oda H, Miyauchi A, Ito Y, Yoshioka K, Nakayama A, Sasai H, et al. Incidences of unfavorable events in the management of low-risk papillary microcarcinoma of the thyroid by active surveillance versus immediate surgery. Thyroid 2016;26:150-155  https://doi.org/10.1089/thy.2015.0313
  10. Cho SJ, Suh CH, Baek JH, Chung SR, Choi YJ, Chung KW, et al. Active surveillance for small papillary thyroid cancer: a systematic review and meta-analysis. Thyroid 2019;29:1399-1408  https://doi.org/10.1089/thy.2019.0159
  11. Tufano RP, Clayman G, Heller KS, Inabnet WB, Kebebew E, Shaha A, et al. Management of recurrent/persistent nodal disease in patients with differentiated thyroid cancer: a critical review of the risks and benefits of surgical intervention versus active surveillance. Thyroid 2015;25:15-27  https://doi.org/10.1089/thy.2014.0098
  12. Ahmadi S, Gonzalez JM, Talbott M, Reed SD, Yang JC, Scheri RP, et al. Patient preferences around extent of surgery in low-risk thyroid cancer: a discrete-choice experiment. Thyroid 2020;30:1044-1052  https://doi.org/10.1089/thy.2019.0590
  13. Kim JH, Baek JH, Sung JY, Min HS, Kim KW, Hah JH, et al. Radiofrequency ablation of low-risk small papillary thyroidcarcinoma: preliminary results for patients ineligible for surgery. Int J Hyperthermia 2017;33:212-219  https://doi.org/10.1080/02656736.2016.1230893
  14. Sun J, Liu X, Zhang Q, Hong Y, Song B, Teng X, et al. Papillary thyroid carcinoma treated with radiofrequency ablation in a patient with hypertrophic cardiomyopathy: a case report. Korean J Radiol 2016;17:558-561  https://doi.org/10.3348/kjr.2016.17.4.558
  15. Tong M, Li S, Li Y, Li Y, Feng Y, Che Y. Efficacy and safety of radiofrequency, microwave and laser ablation for treating papillary thyroid microcarcinoma: a systematic review and meta-analysis. Int J Hyperthermia 2019;36:1278-1286  https://doi.org/10.1080/02656736.2019.1700559
  16. Ito Y, Miyauchi A. Active surveillance of low-risk papillary thyroid microcarcinomas in Japan and other countries: a review. Expert Rev Endocrinol Metab 2020;15:5-12  https://doi.org/10.1080/17446651.2020.1707078
  17. Cho SJ, Baek SM, Lim HK, Lee KD, Son JM, Baek JH. Long-term follow-up results of ultrasound-guided radiofrequency ablation for low-risk papillary thyroid microcarcinoma: more than 5-year follow-up for 84 tumors. Thyroid 2020;30:1745-1751  https://doi.org/10.1089/thy.2020.0106
  18. Bongers PJ, Greenberg CA, Hsiao R, Vermeer M, Vriens MR, Lutke Holzik MF, et al. Differences in long-term quality of life between hemithyroidectomy and total thyroidectomy in patients treated for low-risk differentiated thyroid carcinoma. Surgery 2020;167:94-101  https://doi.org/10.1016/j.surg.2019.04.060
  19. Choi JY, Lee KE, Chung KW, Kim SW, Choe JH, Koo do H, et al. Endoscopic thyroidectomy via bilateral axillo-breast approach (BABA): review of 512 cases in a single institute. Surg Endosc 2012;26:948-955  https://doi.org/10.1007/s00464-011-1973-x
  20. Cho SJ, Baek JH, Chung SR, Choi YJ, Lee JH. Thermal ablation for small papillary thyroid cancer: a systematic review. Thyroid 2019;29:1774-1783  https://doi.org/10.1089/thy.2019.0377
  21. Lim HK, Cho SJ, Baek JH, Lee KD, Son CW, Son JM, et al. US-guided radiofrequency ablation for low-risk papillary thyroid microcarcinoma: efficacy and safety in a large population. Korean J Radiol 2019;20:1653-1661  https://doi.org/10.3348/kjr.2019.0192
  22. Zhou W, Ni X, Xu S, Zhang L, Chen Y, Zhan W. Ultrasound-guided laser ablation versus surgery for solitary papillary thyroid microcarcinoma: a retrospective study. Int J Hyperthermia 2019;36:897-904  https://doi.org/10.1080/02656736.2019.1649475
  23. Choi Y, Jung SL, Bae JS, Lee SH, Jung CK, Jang J, et al. Comparison of efficacy and complications between radiofrequency ablation and repeat surgery in the treatment of locally recurrent thyroid cancers: a single-center propensity score matching study. Int J Hyperthermia 2019;36:359-367  https://doi.org/10.1080/02656736.2019.1571248
  24. Choi Y, Jung SL. Efficacy and safety of thermal ablation techniques for the treatment of primary papillary thyroid microcarcinoma: a systematic review and meta-analysis. Thyroid 2020;30:720-731  https://doi.org/10.1089/thy.2019.0707
  25. Kim JH, Baek JH, Lim HK, Ahn HS, Baek SM, Choi YJ, et al. 2017 thyroid radiofrequency ablation guideline: Korean Society of Thyroid Radiology. Korean J Radiol 2018;19:632-655  https://doi.org/10.3348/kjr.2018.19.4.632
  26. Park HS, Baek JH, Park AW, Chung SR, Choi YJ, Lee JH. Thyroid radiofrequency ablation: updates on innovative devices and techniques. Korean J Radiol 2017;18:615-623  https://doi.org/10.3348/kjr.2017.18.4.615
  27. Papini E, Guglielmi R, Bizzarri G, Graziano F, Bianchini A, Brufani C, et al. Treatment of benign cold thyroid nodules: a randomized clinical trial of percutaneous laser ablation versus levothyroxine therapy or followup. Thyroid 2007;17:229-235  https://doi.org/10.1089/thy.2006.0204
  28. Kong SH, Ryu J, Kim MJ, Cho SW, Song YS, Yi KH, et al. Longitudinal assessment of quality of life according to treatment options in low-risk papillary thyroid microcarcinoma patients: active surveillance or immediate surgery (interim analysis of MAeSTro). Thyroid 2019;29:1089-1096  https://doi.org/10.1089/thy.2018.0624
  29. Jeong SY, Baek JH, Choi YJ, Chung SR, Sung TY, Kim WG, et al. Radiofrequency ablation of primary thyroid carcinoma: efficacy according to the types of thyroid carcinoma. Int J Hyperthermia 2018;34:611-616  https://doi.org/10.1080/02656736.2018.1427288
  30. Zhang M, Luo Y, Zhang Y, Tang J. Efficacy and safety of ultrasound-guided radiofrequency ablation for treating low-risk papillary thyroid microcarcinoma: a prospective study. Thyroid 2016;26:1581-1587  https://doi.org/10.1089/thy.2015.0471
  31. Li J, Liu Y, Liu J, Yang P, Hu X, Qian L. A comparative study of short-term efficacy and safety for thyroid micropapillary carcinoma patients after microwave ablation or surgery. Int J Hyperthermia 2019;36:640-646  https://doi.org/10.1080/02656736.2019.1626492
  32. Zhang M, Tufano RP, Russell JO, Zhang Y, Zhang Y, Qiao Z, et al. Ultrasound-guided radiofrequency ablation versus surgery for low-risk papillary thyroid microcarcinoma: results of over 5 years' follow-up. Thyroid 2020;30:408-417  https://doi.org/10.1089/thy.2019.0147
  33. Ma B, Wei W, Xu W, Wang Y, Guan H, Fan J, et al. Surgical confirmation of incomplete treatment for primary papillary thyroid carcinoma by percutaneous thermal ablation: a retrospective case review and literature review. Thyroid 2018;28:1134-1142  https://doi.org/10.1089/thy.2017.0558
  34. Kim EK. Re: papillary thyroid carcinoma treated with radiofrequency ablation in a patient with hypertrophic cardiomyopathy: a case report. Korean J Radiol 2016;17:965 
  35. Valcavi R, Piana S, Bortolan GS, Lai R, Barbieri V, Negro R. Ultrasound-guided percutaneous laser ablation of papillary thyroid microcarcinoma: a feasibility study on three cases with pathological and immunohistochemical evaluation. Thyroid 2013;23:1578-1582  https://doi.org/10.1089/thy.2013.0279
  36. Vaccarella S, Franceschi S, Bray F, Wild CP, Plummer M, Dal Maso L. Worldwide thyroid-cancer epidemic? The increasing impact of overdiagnosis. N Engl J Med 2016;375:614-617 https://doi.org/10.1056/NEJMp1604412